ENTRY       D03235                      Drug
NAME        Filgrastim (USP/INN);
            Filgrastim (genetical recombination) (JP18);
            Filgrastim (genetical recombination) [Filgrastim biosimilar 1] (JAN);
            Tbo-filgrastim;
            Filgrastim (genetical recombination) [Filgrastim biosimilar 2] (JAN);
            Filgrastim (genetical recombination) [Filgrastim biosimilar 3] (JAN);
            Filgrastim-sndz;
            Filgrastim-aafi;
            Neupogen (TN);
            Nivestym (TN);
            Grastofil (TN);
            Zarxio (TN)
PRODUCT     GRANIX (Cephalon)
            NEUPOGEN (Amgen)
            NIVESTYM (Pfizer Laboratories Div Pfizer)
            RELEUKO (Amneal Pharmaceuticals LLC)
            ZARXIO (Sandoz)
FORMULA     C845H1339N223O243S9
EXACT_MASS  18786.6761
MOL_WEIGHT  18798.6065
SEQUENCE    MTPLGPASSL PQSFLLKCLE QVRKIQGDGA ALQEKLCATY KLCHPEELVL LGHSLGIPWA
            PLSSCPSQAL QLAGCLSQLH SGLFLYQGLL QALEGISPEL GPTLDTLQLD VADFATTIWQ
            QMEELGMAPA LQPTQGAMPA FASAFQRRAG GVLVASHLQS FLEVSYRVLR HLAQP
            (Disulfide bridge: 37-43, 65-75)
  TYPE      Peptide
CLASS       Immunological agent
             DG01753  Colony stimulating factor
              DG01781  Granulocyte colony stimulating factor (G-CSF)
REMARK      Therapeutic category: 3399
            ATC code: L03AA02
            Product: D03235<JP/US>
EFFICACY    Antineutropenic, Hematopoietic stimulant, Antineoplastic (enhancer), Granulocyte colony stimulating factor (G-CSF)
  DISEASE   Neutropenia [DS:H00100]
COMMENT     recombinant granulocyte colony stimulating factor (G-CSF) [HSA:1440] [KO:K05423]
TARGET      CSF3R (GCSFR, CD114) [HSA:1441] [KO:K05061]
  PATHWAY   hsa04060(1441)  Cytokine-cytokine receptor interaction
            hsa04151(1441)  PI3K-Akt signaling pathway
            hsa04630(1441)  JAK-STAT signaling pathway
            hsa04640(1441)  Hematopoietic cell lineage
            hsa05200(1441)  Pathways in cancer
BRITE       Anatomical Therapeutic Chemical (ATC) classification [BR:br08303]
             L ANTINEOPLASTIC AND IMMUNOMODULATING AGENTS
              L03 IMMUNOSTIMULANTS
               L03A IMMUNOSTIMULANTS
                L03AA Colony stimulating factors
                 L03AA02 Filgrastim
                  D03235  Filgrastim (USP/INN) &lt;JP/US&gt;
            USP drug classification [BR:br08302]
             Immunological Agents
              Immunostimulants
               Colony-stimulating Factors
                Filgrastim
                 D03235  Filgrastim (USP/INN)
            Therapeutic category of drugs in Japan [BR:br08301]
             3  Agents affecting metabolism
              33  Blood and body fluid agents
               339  Miscellaneous
                3399  Others
                 D03235  Filgrastim (USP/INN); Filgrastim (genetical recombination) (JP18); Filgrastim (genetical recombination) [Filgrastim biosimilar 1] (JAN); Filgrastim (genetical recombination) [Filgrastim biosimilar 2] (JAN); Filgrastim (genetical recombination) [Filgrastim biosimilar 3] (JAN)
            Drug groups [BR:br08330]
             Immunological agent
              DG01753  Colony stimulating factor
               DG01781  Granulocyte colony stimulating factor (G-CSF)
                D03235  Filgrastim
            Drug classes [BR:br08332]
             Immunological agent
              DG01753  Colony stimulating factor
               D03235  Filgrastim
            Target-based classification of drugs [BR:br08310]
             Cytokines and receptors
              Cytokine receptors
               CSF and other factor receptors
                CSF3R (GCSFR, CD114)
                 D03235  Filgrastim (USP/INN) &lt;JP/US&gt;
            Drugs listed in the Japanese Pharmacopoeia [BR:br08311]
             Chemicals
              D03235  Filgrastim (genetical recombination)
              D03235  Filgrastim (genetical recombination) injection
            New drug approvals in the USA [br08319.html]
             New molecular entities and new therapeutic biological products
              D03235
            New drug approvals in Europe [br08329.html]
             European public assessment reports (EPAR) authorised medicine
              D03235
            New drug approvals in the USA, Europe and Japan [br08328.html]
             Approval dates by FDA, EMA and PMDA
              D03235
DBLINKS     CAS: 121181-53-1
            PubChem: 17397388
///
